|
"There could be no more important challenge than trying to harness the incredible potential of new information tools to enable better, more affordable,
less error prone healthcare."
Dr. Mark McClellan, FDA at CDISC Interchange 2003 Thanks to landmark studies that have highlighted the shortcomings of traditional paper-and-pencil diaries in pharmaceutical trials, change is in the wind. Data technology companies are talking. Big pharma is listening. And organizations like the Clinical Data Interchange Standards Consortium (CDISC) are moderating the enlightened conversation.A groundswell of regulatory news and commentary is documenting the inroads being achieved by the up and coming ePRO industry. Coming soon is an archive of key articles and editorial, which have been published in light of the momentum toward electronic drug trials. |
